The engine of the biosimilar sector is the same as with small molecule drugs, patent expiry. On this basis, prospects for biosimilars look good, with the vast majority of leading originator brands in the global biologics market expected to lose some degree of protection by 2019.
The US generics market was estimated at US$18.1 billion in 2004; the leading European generics markets together totalled between US$10-US$11 billion for the same period. This new report asks why there is such a difference in value?
Indian pharmaceutical companies are grabbing headlines on an almost daily basis and are increasingly carving out market shares for themselves in the US and many other markets around the world.